36.1 F
New York
Wednesday, January 20, 2021

Penny Stock Focus on Cannabis Science Inc (OTCMKTS:CBIS)

Must read

Why Is Everyone Talking About Alpine 4 Technologies Ltd (OTCMKTS:ALPP) Stock?

Investors who are looking for fast-moving stocks have had have made options in recent days. One stock that certainly stands out is...

Nano One Materials Corp (OTCMKTS:NNOMF) Signs Cathode Evaluation Agreement: Stock Reacts

Over the past week, there have been many stocks that have managed to generate significant gains and one of those is Nano...

Grayscale Bitcoin Trust (OTCMKTS:GBTC) Extends Rally As Bitcoin Jumps

One of the bigger stories of the year so far has been the massive gains made by Bitcoin. This week BTC hit...

Plyzer Technologies Inc (OTCMKTS:PLYZ) Gains Momentum on High Volume: Now What?

One of the more notable gainers this week on the OTC is Plyzer Technologies Inc (OTCMKTS:PLYZ). The stock was in focus among...

Cannabis Science Inc (OTCMKTS:CBIS) has been around longer than any other Cannabis company, and we’ve covered the trading action in Cannabis Science Inc shares since 2012. I really cannot think of a more representative stock hanging around longer than CBIS. The company is listed on the OTCBB Pinksheets, which essential means they are in the non-filing category, but that doesn’t deter investors from Cannabis Science. When news about the industry grabs hold in the media cycle traders flock to grab shares.

A look at any longer term chart shows the rise in prices and volume dating back to April 2012, and again in February 2014, when you had rising prices in the entire sector, which was the first drive up in cannabis.

Cannabis had the 2014 rally, and the 2016 rally which occurred (logically) during the election cycle in November 2016 – where shares in CBIS had a 4x move on a surge in volume. Cannabis Science is a retail investment for many who wanted to jump on the Cannabis train, and own a piece of the action.

Cannabis Science Inc (OTCMKTS:CBIS) specializes in the development of cannabis-based medicines, and recently announced the anticipated delivery of the first of pre-designed greenhouses with full tracking and reporting protocols for the California and Nevada operations.

“Having control over our own supply chain will greatly increase our efficiencies, including the time and cost required to have processed product readily available for development into all our formulations. We will soon launch our observational studies for specific cannabinoid combinations targeting critical ailments. We will be growing a variety of cannabinoid combinations for our formulations and testing. Each formulation is designed to target a specific critical ailment; to work using a particular delivery mode; and to have the potency to drive maximum positive results in patient usage,” stated CMO Dr. Allen Herman.

CBIS, Inc. said it has received several hundred emails inquiring about the timing of clinical research and the availability of treatment options. These inquiries cover the management of pain, peripheral neuropathies, cancer, and COPD. All inquiries are entered into our in-house database and we will be responding to each person as each targeted observational study officially commences. The studies will include some of the over 500 cannabinoids that have been isolated and identified from Cannabis sativa. The cannabinoids belong to the chemical class of terpenophenolics, of which 85 have been uniquely identified in cannabis. Common plant cannabinoids (phytocannabinoids) include: tetrahydrocannabinol (THC), cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), and cannabinol (CBN).

Find out when Cannabis Science Inc stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

$CBIS 10-Day Chart Below:

The pharmacology of THC has been widely studied, and it is regarded as the main psychoactive constituent of cannabis. Our in-house database will form the basis of patient-centered outcomes research (PCOR) for a variety of critical conditions.

According to corporate materials; CBIS will then develop protocols for an international consortium of US, South African, and European universities and research institutions. This consortium will develop research protocols for animal studies and clinical trials for several critical clinical ailments concurrently.

The Cannabis Science Research Laboratory will have principal investigators at each partner institution and will work closely with CBIS leadership. Our initial animal studies will focus on cancers, and our clinical trials will concentrate on Cancers, PTSD, pain management, HIV/AIDS, and neurological conditions including sleep disorders. CBIS will then add other targeted ailments for clinical trials as the demand and need is identified in each jurisdiction. Each country that we collaborate in will ensure that the research is done within the approval guidelines for that country and follows the approval guidelines for the US Food and Drug Administration providing nationwide federal government approvals.

Their initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively. On January 3, 2017, Cannabis Science entered into a CRA with Dana-Farber, one of the world’s leading cancer centers. Under the terms of the CRA, Cannabis Science and Dana-Farber will jointly investigate and develop use of cannabinoids to treat various forms of cancers.

“I am excited about Cannabis Science’s relationship with Dana-Farber. When I first met Wilfred Ngwa, PhD, Director of Global Health Catalyst at Harvard Medical School and Principal Investigator for the CRA, we immediately realized potential synergies on cancer research interests, and the potential to collaborate to develop cannabinoid-based medicines to treat cancer and control cancer symptoms with minimal side-effects,” stated Dabney.

These important steps, and the size of the shareholder base makes CBIS one of the widely held names in the sector. Trading at a $153 million market cap the stock has been in decline mode in much of 2017, but a look at the sector in general shows that nearly all stocks in the sector are lower.

The bottom line is, it’s astounding that these companies can have these large floats for this developing industry. A look closer sees the company has 2 billion + shares out, making it one to watch anytime the Cannabis Sector comes in focus functioning as the most widely held. Since many readers are in the stock, we will continue our coverage of it’s price action during the cannabis sector boom. For continuing coverage on shares of Cannabis Science Inc stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!

Latest article

Signal Advance Inc (OTCMKTS:SIGL) Makes a Big Move, Again.

Speculation and confusion can often lead to strange occurrences on the stock markets and that is what happened...

Ozop Energy Solutions Inc (OTCMKTS:OZSC) Remains Volatile: Stock in Focus

Those who are looking to discover stocks that may have made big moves over the course of the past week could consider...

Data Storage Corp (OTCMKTS:DTST) Gets Sudden Attention: What’s The Buzz?

One of the stocks to have made significant gains this week was that of Data Storage Corp (OTCMKTS:DTST). The Data Storage Corporation...

A Closer Looks at American Battery Metals Corp (OTCMKTS:ABML) Developments

American Battery Metals Corp (OTCMKTS:ABML) is one of the stocks to have been in focus among investors over the course of the...

Why is Grayscale Ethereum Trust (ETH) (OTCMKTS:ETHE) In a Bearish Trend?

The Bitcoin rally over the past weeks has taken the crypto space by storm. However, it should not be forgotten that Ethereum,...